Characterization of a new potent heparin. 5th Communication: Further characterization by affinity chromatography on antithrombin-sepharose and its comparison with a commercially available heparin. 1980

A S Bhargava, and G Freihube, and P Günzel

A highly potent heparin (Heparin Schering) was characterized in comparison to commercial heparin by affinity chromatography on antithrombin-III-sepharose. Heparin Schering consists of 83% high affinity and 17% low affinity fractions, whereas commercial heparin contained only 40% high affinity heparin and 60% low affinity heparin. The specific biological activities per microgram uronic acid and elution pattern on antithrombin-sepharose of high affinity heparin fraction were similar for both heparin preparations. It is concluded that the 2 times more potent anticoagulant activity of heparin Schering is mainly due to the enrichment of high affinity fraction (83%), which is also present in commercial heparin but at a remarkably lower percentage (40%).

UI MeSH Term Description Entries
D002846 Chromatography, Affinity A chromatographic technique that utilizes the ability of biological molecules, often ANTIBODIES, to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Chromatography, Bioaffinity,Immunochromatography,Affinity Chromatography,Bioaffinity Chromatography
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct
D012685 Sepharose Agarose,Sepharose 4B,Sepharose C1 4B,4B, Sepharose C1,C1 4B, Sepharose
D014574 Uronic Acids Acids derived from monosaccharides by the oxidation of the terminal (-CH2OH) group farthest removed from the carbonyl group to a (-COOH) group. (From Stedmans, 26th ed) Uronic Acid,Acid, Uronic,Acids, Uronic

Related Publications

A S Bhargava, and G Freihube, and P Günzel
August 1980, Journal of chromatography,
A S Bhargava, and G Freihube, and P Günzel
July 1987, Cell differentiation,
A S Bhargava, and G Freihube, and P Günzel
October 1987, Thrombosis research,
A S Bhargava, and G Freihube, and P Günzel
February 1978, Scandinavian journal of clinical and laboratory investigation,
A S Bhargava, and G Freihube, and P Günzel
October 1982, Journal of immunological methods,
A S Bhargava, and G Freihube, and P Günzel
March 1980, Journal of lipid research,
A S Bhargava, and G Freihube, and P Günzel
January 1986, Annales pharmaceutiques francaises,
A S Bhargava, and G Freihube, and P Günzel
October 1979, Canadian journal of biochemistry,
Copied contents to your clipboard!